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The attainment of this goal was evaluated on the basis of both height deficiency reduction under therapy and the decreased prevalence of patients with short stature at the end of therapy.
On the contrary, data concerning the prediction of adult stature were not kept into any consideration in order to demonstrate the efficacy of early GH therapy, since predicting final height in any individual is far from an exact science.
Abbott et al. (2) have objected to the fact that predicted adult height in our study was calculated at yearly intervals. According to their comments, in fact, our girls under GH therapy were growing very differently to the untreated girls from which the Lyon equation is derived.
From a methodological point of view this criticism is correct, but it is to be underlined that this methodological remark cannot minimally invalidate the conclusions of our study, which were not based on the evolution of predicted height under GH treatment.
Moreover, as clearly written in the legend to Table 2 , significance levels for predicted adult height in our study were not calculated at yearly intervals, but were calculated between baseline values and the ones recorded at a time when GH treatment had been withdrawn.
